JTCR016
Drug
Celgene Corporation
Total Payments
$15,663
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $15,663 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15,663 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1 Study of JTCR016 in Patients with Advanced Solid Tumors-JTCR016-(2727) | Celgene Corporation | $15,663 | 0 |
Top Doctors Receiving Payments for JTCR016
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $15,663 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $15,663
Product Information
- Type Drug
- Total Payments $15,663
- Total Doctors 0
- Transactions 1
About JTCR016
JTCR016 is a drug associated with $15,663 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2019 to 2019. In 2019, $15,663 was paid across 1 transactions to 0 doctors.
The most common payment nature for JTCR016 is "Unspecified" ($15,663, 100.0% of total).
JTCR016 is associated with 1 research study, including "A Phase 1 Study of JTCR016 in Patients with Advanced Solid Tumors-JTCR016-(2727)" ($15,663).